CompletedNot Applicable

Impact of the COVID-19 Pandemic on Central Precocious Puberty: a Retrospective Cohort Study from Turkey

Turkey (Türkiye)192 participantsStarted 2018-03-01

Plain-language summary

Objective: This study investigates the clinical and demographic characteristics of girls diagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periods to assess potential changes during the COVID-19 pandemic.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria (Who Can Participate?) Girls: Tanner stage ≥2 before age 8 peak LH \> on gnrh analog test, basal Lh \>0,3 Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital malformations, oncological diseases, neurosurgical or genetic disorders, or medications affecting puberty were excluded from the study

What they're measuring

Mean Age at Pubertal Onset

Timeframe: 4 years

Trial details

NCT IDNCT06823076

SponsorUmraniye Education and Research Hospital

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2022-03-01

View on ClinicalTrials.gov More COVID19- Infection with SARS-CoV-2 Virus trials